{Reference Type}: Journal Article
{Title}: MET alterations in advanced non-small cell lung cancer.
{Author}: Chagas GCL;Rangel AR;El Osta B;
{Journal}: Curr Probl Cancer
{Volume}: 49
{Issue}: 0
{Year}: 2024 04 12
{Factor}: 2.367
{DOI}: 10.1016/j.currproblcancer.2024.101075
{Abstract}: Precision medicine has helped identify several tumor molecular aberrations to be treated with targeted therapies. These therapies showed substantial improvement in efficacy without excessive toxicity in patients with specific oncogenic drivers with advanced cancers. In metastatic lung cancers, the implementation of broad platforms for molecular tumor sequencing has helped oncology providers identify oncogenic drivers linked with better outcomes when treated upfront with targeted therapies. Mesenchymal-epithelial transition factor (MET) alterations are present in up to 60% of non-small cell lung cancer and are associated with a poor prognosis. Capmatinib and tepotinib are currently the only two approved targeted therapies by the U.S. Food and Drug Administration (FDA) for patients with MET exon 14 skipping mutation. Several agents are being developed to tackle an unmet need in patients with MET alterations. Some of these agents are being used in combination with EGFR targeted therapy to mitigate resistance to EGFR inhibitor. These agents are poised to provide new hope for these patients.